Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Dec 2;8(12):e75540.
doi: 10.1371/journal.pone.0075540. eCollection 2013.

Treatment of anemia in inflammatory bowel disease--systematic review and meta-analysis

Tomer Avni  1 , Amir Bieber, Tali Steinmetz, Leonard Leibovici, Anat Gafter-Gvili
Affiliations
Meta-Analysis

Treatment of anemia in inflammatory bowel disease--systematic review and meta-analysis

Tomer Avni et al. PLoS One. .

Abstract

Background: Anemia is considered the most common systemic complication of inflammatory bowel disease (IBD). We aimed to provide all available evidence regarding the safety and efficacy of therapy existing today to correct anemia in IBD.

Methods: Systematic review and meta-analysis of randomized controlled trials that compared any treatment for anemia in patients with IBD. We searched electronic databases, conference proceedings and clinical trials registries. Two reviewers independently extracted data from included trials. The primary outcome was the effect of treatment for anemia in IBD on the hemoglobin (Hb) response, defined as rate of patients who achieved an increase of 2 g/dl in Hb concentration at the end of the follow-up. Secondary outcomes included disease severity scores, iron indices, Hb levels, inflammatory markers, adverse effects, and mortality. Dichotomous data were analysed by calculating the relative risk (RR) for each trial with the uncertainty in each result being expressed using 95% confidence intervals (CI). A fixed effect model was used, except in the event of significant heterogeneity between the trials (P<0.10, I(2)>40%), in which we used a random effects model.

Results: Nine trials fulfilled the inclusion criteria, to a total of 973 patients. We were able to perform meta-analysis for intravenous (IV) versus oral iron and for ESAs versus placebo. IV iron was associated with a higher rate of achieving Hb response in comparison to oral iron; RR 1.25 (95% CI 1.04-1.51, I(2) = 2%, 4 trials), CRP levels and disease activity indexes were not significantly affected by IV iron. IV iron was associated with a decrease in adverse events that required discontinuation of intervention and without an increase in serious adverse.

Discussion: Treatment for anemia in IBD should include IV iron and not oral iron replacement, due to improved Hb response, no added toxicity and no negative effect on disease activity.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA flow diagram.
Figure 2
Figure 2. Risk of bias assessment.
Figure 3
Figure 3. IV iron versus PO iron, Hb response at end of follow-up.
Figure 4
Figure 4. A IV iron versus PO iron, serious AEs; b AEs requiring discontinuation.
See this image and copyright information in PMC

Comment in

  • On both sides of the ocean.
    Jimenez K, Gasche C, Auerbach M. Jimenez K, et al. Blood Transfus. 2016 May;14(2):197-8. doi: 10.2450/2016.0304-15. Epub 2016 Apr 28. Blood Transfus. 2016. PMID: 27177396 Free PMC article. No abstract available.

References

    1. Gasche C (2000) Complications of inflammatory bowel disease. Hepatogastroenterology 47: 49–56. - PubMed
    1. Gasche C, Lomer MC, Cavill I, Weiss G (2004) Iron, anaemia, and inflammatory bowel diseases. Gut 53: 1190–1197. - PMC - PubMed
    1. Ohira Y, Edgerton VR, Gardner GW, Senewiratne B, Barnard RJ, et al. (1979) Work capacity, heart rate and blood lactate responses to iron treatment. Br J Haematol 41: 365–372. - PubMed
    1. Wells CW, Lewis S, Barton JR, Corbett S (2006) Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 12: 123–130. - PubMed
    1. Cucino C, Sonnenberg A (2001) Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 7: 250–255. - PubMed